MTOR and skin squamous cell carcinoma: mTOR inhibitors such as sirolimus and everolimus have been associated with a lower incidence of cSCC and subsequent nonmelanoma skin cancers, compared with calcineurin inhibitors and other older immunosuppressants, in multiple studies [27,28,29,30,31].